JAZZ Stock Recent News

DUBLIN , March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

MPLX, LDOS, JAZZ, FTNT and PPC are some of the stocks with high ROE to profit from as markets falter on tariff concerns.

Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.

The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) study Novel analysis of real-world Epidiolex treatment patterns underscore importance of dose optimization for improved patient persistence For U.S. media and investors only DUBLIN , March 19, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, evaluating the effectiveness and safety of low-sodium oxybate, Xywav® (calcium,

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Despite a correction to begin the year, there are a few pockets of the market that are working.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to.